Home › Funds › E. Ohman J:or Asset Management AB › CYTK

E. Ohman J:or Asset Management AB position in CYTK

CYTOKINETICS INC · Health Care

E. Ohman J:or Asset Management AB reported holding 305,255 shares of CYTK (CYTOKINETICS INC) in its Q3 2026 13F filing — a position valued at US$20.1M, representing 0.45% of its reported portfolio and ranking #47 among its reported holdings. E. Ohman J:or Asset Management AB has disclosed CYTK holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

Latest position (Q3 2026)305.25K sh
Reported value held$20.12M
Portfolio Weight0.45%
First reportedQ1 2025
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How E. Ohman J:or Asset Management AB's CYTK position evolved

E. Ohman J:or Asset Management AB first disclosed a stake in CYTK in Q1 2025 at 329,231 shares (US$13.2M). The position peaked in Q2 2026 at 304,611 shares, worth US$25.9M. Across 7 filings, E. Ohman J:or Asset Management AB increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 305,255 shares valued at US$20.1M.

Quarter by quarter

QuarterSharesValueChange
Q1 2025 329.23K $13.23M New
Q2 2025 407.04K $13.45M Add
Q3 2025 407.04K $22.37M Hold
Q4 2025 362.96K $23.06M Reduce
Q1 2026 300.76K $19.82M Reduce
Q2 2026 304.61K $25.95M Add
Q3 2026 305.25K $20.12M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CYTK and 13F data

CYTK (CYTOKINETICS INC) is a Health Care company. 44 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CYTK

All CYTK fund holders →

FAQ

How long has E. Ohman J:or Asset Management AB held CYTK?

E. Ohman J:or Asset Management AB has disclosed CYTK holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

What is E. Ohman J:or Asset Management AB's current position in CYTK?

As of Q3 2026, E. Ohman J:or Asset Management AB holds 305.25K shares of CYTK (CYTOKINETICS INC), valued at $20.12M, representing 0.45% of its reported portfolio and ranking #47.

Has E. Ohman J:or Asset Management AB been buying or selling CYTK?

In the latest 13F filing (Q3 2026), E. Ohman J:or Asset Management AB held unchanged its position in CYTK. The position peaked in Q2 2026 at 304.61K shares.

Which other funds hold CYTK?

Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.